团队介绍：

团队从事传染病和公共卫生应急、不明原因发热诊、疑难重症感染性疾病诊疗和各种肝病诊疗和研究工作。致力于慢性肝炎抗病毒治疗、肝纤维化无创诊断和治疗、肝病免疫发病机理和免疫治疗等工作。

项目情况：

牵头国家“十三五”、“十二五”传染病重大专项课题2项，参加国家“十二五”和“十一五”传染病重大专项课题3项，牵头科技部应急专项2项；主持卫生部临床学科重点项目，国家自然科学基金项目，国家“863”项目和美国CMB基金项目等多项课题。

招生信息（拟招生的研究方向）：

1. 乙肝免疫及治疗相关研究等

2. 干细胞治疗自身免疫性肝病研究等

科研项目：

1. 国家自然科学基金面上项目：乙型肝炎核心抗体定量评估肝组织炎症的机制研究；编号：82270626，直接经费53万。

2. 主持科技部应急专项“法匹拉韦联合托珠单抗治疗新型冠状病毒肺炎的多中心、随机、对照临床试验研究” 课题编号：2020TFC0844100；中央经费：300万。

3. 主持科技部应急专项“COVID-19患者出院后核酸‘复阳’的发生机制、临床转归和治疗干预的研究（2020YFC0846800）；中央经费：500万

4. 主持国家＂十三五＂传染病重大专项课题＂精准诊断和逆转乙肝肝纤维化/肝硬化的研究＂，总经费2629.58万。课题编号：2017ZX10203202.

5. 主持国家“十二五”传染病重大专项课题“建立HBV相关肝脏纤维化无创诊断标准／模型的研究”。课题负责人，课题编号：2013ZX10002005，经费：1336万

6. 参加国家“十三五”传染病重大专项课题“乙型肝炎临床诊断及监测新型试剂的研发”2017ZX10302201003003 ，经费119.46 万元。

7. 参加北京市科学技术委员会课题：肝病创新药物早期临床试验与关键技术研究。经费：100万

8. 参与科技部攻关项目：新型冠状病毒肺炎临床进展、转归、预后及其影响因素的大样本研究。经费30万。

9. 主持中关村精准医学基金会项目：安络化纤丸治疗COVID-19康复期患者疗效和安全性的多中心、开放、随机对照研究。经费：60万。

10. 参加国家“十三五”传染病重大专项课题“乙型肝炎临床诊断及监测新型试剂的研发”2017ZX10302201003003 ，经费119.46 万元。

11. 参加国家“十二五”传染病重大专项课题“防治乙型肝炎新技术、新方法的研究”，课题编号：2012ZX10002006。课题负责人，经费：71.5万。

代表性研究成果：

近五年代表性论文：

1. Wang, Guiqiang; Zhao, Kexin; Han, Jun; Hu, Zhongyu; Zhang, Tianzuo; Wang, Yanchao; Shi, Rui; Li, Yanhua; Song, Qinqin; Du, Haijun; He, Peng; Xu, Shuping; Yang, Xinjie; Fu, Yongpan; Cui, Yimin; Xie, Liangzhi. Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled,  phase I clinical trial. The Journal of infection   影响因子: 38.637

2. Li, Zhi; Zhang, Chi; Liu, Yiqi; Wang, Fang; Zhao, Baoling; Yang, Junmei; Zhao, Yongjing; Zhao, Hong; Wang, Guiqiang. Diagnostic and Predictive Values of Ferroptosis-Related Genes in Child Sepsis. Frontiers in immunology 影响因子: 8.786

3. Zhang, Chi; Liu, Yiqi; Li, Jiawen; Liu, Hui; Shao, Chen; Liu, Dan; Yu, Min; Xi, Hongli; Zhao, Hong; Wang, Guiqiang. Dose-response relationship between qAnti-HBc and liver inflammation in chronic hepatitis B with normal or mildly elevated alanine transaminase based on liver  biopsy. Journal of medical virology 影响因子: 20.693

4. Wang, Guiqiang; Duan, Zhongping. Guidelines for Prevention and Treatment of Chronic Hepatitis B. Journal of clinical and translational hepatology 影响因子: 5.065

5. Wang, Guiqiang; Tanaka, Atsushi; Zhao, Hong; Jia, Jidong; Ma, Xiong; Harada, Kenichi; Wang, Fu-Sheng; Wei, Lai; Wang, Qixia; Sun, Ying; Hong, Yuan; Rao, Huiying; Efe, Cumali; Lau, George; Payawal, Diana; Gani, Rino; Lindor, Keith; Jafri, Wasim; Omata, Masao; Sarin, Shiv Kumar. The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatology international 影响因子: 9.029

6. Zhao, Hong; Zhang, Chi; Zhu, Qi; Chen, Xianxiang; Chen, Guilin; Sun, Wenjin; Xiao, Zuohan; Du, Weijun; Yao, Jing; Li, Guojun; Ji, Yanhua; Li, Niuniu; Jiang, Yujin; Wang, Ying; Zeng, Qingjin; Li, Wei; Gong, Beilei; Chang, Xianyou; Zhu, Feng; Jiang, Xiufeng; Li, Jiawen; Wu, Zhao; Liu, Yingxia; Peng, Peng; Wang, Guiqiang. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial. International immunopharmacology 影响因子: 5.714

7. Zhao, Hong; Zhang, Chi; Chen, Xian-Xiang; Zhu, Qi; Huang, Wen-Xiang; Zeng, Yi-Lan; Liu, Ying-Xia; Li, Guo-Jun; Du, Wei-Jun; Yao, Jing; Li, Jia-Wen; Peng, Peng; Wang, Gui-Qiang. The relationship between SARS-COV-2 RNA positive duration and the risk of recurrent positive. Infectious diseases of poverty  影响因子: 10.485

8. Zhang, Chi; Wu, Zhao; Li, Jia-Wen; Tan, Kangan; Yang, Wanna; Zhao, Hong; Wang, Gui-Qiang. Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19. Journal of medical virology 影响因子: 20.693

9. Zhao, Hong; Zhu, Qi; Zhang, Chi; Li, Jiawen; Wei, Ming; Qin, Yuhong; Chen, Guilin; Wang, Ke; Yu, Junhua; Wu, Zhao; Chen, Xianxiang; Wang, Guiqiang. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. Biomedicine & pharmacotherapy 影响因子: 7.419

10. Cheng, Hao; Wang, Yan; Wang, Gui-Qiang. Reply to: "Reporting of all cardiac medications and their outcome in COVID-19". Journal of medical virology  影响因子: 20.693

11. Zhang, Chi; Wu, Zhao; Li, Jia-Wen; Zhao, Hong; Wang, Gui-Qiang. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. International journal of antimicrobial agents影响因子: 15.441

专利：国家发明专利6项，实用新型专利1项

主编的科普图书《活出健康—免疫力就是好医生》荣获中华医学科技奖医学科普奖，北京医学科技奖医学科普奖，第七届中国科普作家协会优秀科普作品奖“科普图书类金奖”；科技部“全国优秀科普作品”奖等多项奖项。